Quantinno Capital Management LP Has $52.05 Million Stock Position in Novartis AG $NVS

Quantinno Capital Management LP raised its holdings in Novartis AG (NYSE:NVS) by 13.1% during the first quarter, HoldingsChannel reports. The firm owned 340,728 shares of the company’s stock after acquiring an additional 39,537 shares during the quarter. Quantinno Capital Management LP’s holdings in Novartis were worth $52,046,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Arlington Trust Co LLC bought a new stake in shares of Novartis during the 4th quarter worth $25,000. Archer Investment Corp raised its stake in Novartis by 93.0% during the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after acquiring an additional 80 shares in the last quarter. CrossGen Wealth LLC acquired a new position in Novartis during the fourth quarter worth about $28,000. Bank of Jackson Hole Trust lifted its holdings in shares of Novartis by 425.0% in the fourth quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 187 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in shares of Novartis in the 3rd quarter valued at approximately $33,000. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

NVS stock opened at $158.82 on Thursday. The stock has a 50-day moving average price of $152.44 and a 200-day moving average price of $152.58. Novartis AG has a 1-year low of $112.34 and a 1-year high of $170.46. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. The firm has a market cap of $303.06 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 2.75 and a beta of 0.45.

Novartis (NYSE:NVS) last announced its earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%. As a group, equities research analysts expect that Novartis AG will post 8.8 earnings per share for the current year.

Analyst Ratings Changes

NVS has been the subject of several research reports. Citigroup reissued a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Weiss Ratings reiterated a “buy (b)” rating on shares of Novartis in a report on Friday, July 24th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.